News

The nonprofit teaching hospital Holy Cross Health has partnered with the COPD Foundation to open a pilot program to help people with chronic obstructive pulmonary disease (COPD) and related lung disorders in managing their health at their homes. Funded by Herb Yardley, a member of the foundation’s board…

A new, noninvasive breath biopsy panel — dubbed “a Breathalyzer for disease” — can distinguish several airway disorders, including chronic obstructive pulmonary disease (COPD), its developer said. Launched by Owlstone Medical, the panel may help in diagnosing COPD. The tool, officially called the Respiratory Diseases Research Use Only (RUO)…

A pilot study on the first wireless nebulizer for use by people with chronic obstructive pulmonary disease (COPD) has been cleared by a review board of the U.S. Food and Drug Administration (FDA), Wellinks, the nebulizer’s developer, announced. “Getting into the field with our first digital health offering…

In people with chronic obstructive pulmonary disease (COPD) who experience acute exacerbations, the use of amoxicillin alone is associated with better outcomes than treatment with amoxicillin in combination with clavulanic acid, another antibiotic, a Danish study shows. The study, “Antibiotic treatment in acute exacerbation of COPD:…

Noninvasive ventilation at home, known as NIVH, is associated with a significantly lower risk of death, hospitalization, and emergency room (ER) visits among chronic obstructive pulmonary disease (COPD) patients with chronic respiratory failure, according to a study based on Medicare data. Notably, the NIVH-associated reduced risk of hospitalization was…

People in China with chronic obstructive pulmonary disease (COPD) are overusing inhaled corticosteroids and underusing non-pharmacological therapies such as home oxygen therapy, a study suggests. The real-world data show that treatment of COPD patients fails to follow the 2017 revised Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines.

The protein ADAM17 appears to serve as a switch for chronic obstructive pulmonary disease (COPD), a study in a mouse model of emphysema reports, promoting COPD’s development when activated and alleviating disease features when deficient. An increase in active ADAM17 is also…

The European Commission has approved AstraZeneca‘s triple combination therapy Trixeo Aerosphere as a maintenance treatment for chronic obstructive pulmonary disease (COPD). The approval, which follows a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), covers the therapy’s use in adults with moderate-to-severe COPD…

The inflammatory biomarkers FeNO and EOS can be used as indicators to distinguish people with chronic obstructive pulmonary disease (COPD) from those with COPD combined with asthma, a study has found.  These biomarkers’ diagnostic value, however, was…

The COPD Foundation and Blue Marble Health have partnered to promote pulmonary rehabilitation through a virtual program for people with chronic obstructive pulmonary disease (COPD) during the COVID-19 pandemic. “We hope to enable participation and maximize the benefits of virtual pulmonary rehabilitation by providing a…